Clinical trial
A Prospective, Single-arm, Single-center, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
NCT04566952 is registered in ClinicalTrials.gov with Xiaoxiang Chen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Single-arm, Single-center, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
- Lead sponsor
- Xiaoxiang Chen
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 28, 2020
- Completion date
- October 1, 2023
- Enrollment
- 68 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adnexal diseases, angiogenesis, anlotinib, antineoplastic agents, brca1 mutation, brca2 mutation, carcinoma, carcinoma, ovarian epithelial, genital diseases, female, genital neoplasms, female, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, glandular and epithelial, ovarian and fallopian tube cysts and neoplasms, ovarian cancer, ovarian diseases, parp inhibitors, urogenital neoplasms